TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6870221

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of metronidazole (500 mg over 20 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tinidazole (500 mg over 20 min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral administration of metronidazole (500 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral administration of tinidazole (500 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rectal administration of metronidazole (1,000 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rectal administration of tinidazole (1,000 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravaginal administration of metronidazole (500 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravaginal administration of tinidazole (500 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral administration of either drug
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rectal administration of either drug
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravaginal administration of either drug
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 27
Study: 31005915

Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 0
Study: 29894202

Group type: EXPERIMENTAL
Intervention: Insulin intervention during dual clamp in MHD patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Insulin intervention during dual clamp in controls
Number of subjects: 33
Study: 26781504

Group type: COMPARATOR
Intervention: Advice only
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Advice with exercise
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Advice with multifactorial falls prevention (MFFP)
Number of subjects: 9000
Study: 24717394

Group type: EXPERIMENTAL
Intervention: CFC training for physicians
Number of subjects: 480
Study: 21865014

Group type: EXPERIMENTAL
Intervention: Active Treatment (AT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 122
Study: 20078686

Group type: EXPERIMENTAL
Intervention: C-HAT (currently on heroin-assisted treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: D-HAT (discontinued HAT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: N-HAT (never received HAT)
Number of subjects: 54
Study: 18331607

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15845709

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine plus IV morphine via patient‐controlled analgesia (ITM+PCA group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: IV morphine via patient‐controlled analgesia (PCA‐only group)
Number of subjects: 100
Study: 12219854

Group type: EXPERIMENTAL
Intervention: High self-esteem participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low self-esteem participants
Number of subjects: 0
Study: 10354965

Group type: EXPERIMENTAL
Intervention: Pleconaril oral capsules (50 to 1000 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8550116

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nifedipine (10-20 mg per day)
Number of subjects: 65
Study: 1769321

Group type: EXPERIMENTAL
Intervention: L-sulpiride 25 mg t.i.v./day, p.o. for 30 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 6175830

Group type: EXPERIMENTAL
Intervention: Prazosin 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trimazosin 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: UK-33,274 4 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prazosin and UK-33,274
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 6
Study: 31091866

Group type: EXPERIMENTAL
Intervention: Pseudomonas fluorescens VUPF5 nanocapsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis VRU1 nanocapsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation of metabolites from both bacterial strains
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28043189

Group type: EXPERIMENTAL
Intervention: Andresen Activator (AA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Prefabricated Functional Appliance (PFA)
Number of subjects: 97
Study: 25234481

Group type: EXPERIMENTAL
Intervention: MEHRIT (social-interaction-based intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community treatment group (control)
Number of subjects: 0
Study: 23968815

Group type: EXPERIMENTAL
Intervention: METH (30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: METH (0 mg)
Number of subjects: 8
Study: 20223794

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural (CBT) Anger Management group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Personal Development (PD) Anger Management group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 19689661

Group type: EXPERIMENTAL
Intervention: 300 mg loading dose of clopidogrel followed by 150 mg daily for 1 week prior to angiography
Number of subjects: 120

Group type: COMPARATOR
Intervention: 300 mg loading dose of clopidogrel
Number of subjects: 120
Study: 17804841

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U weekly for a maximum of 3 weeks)
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study: 15028824

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (fluorouracil)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Both chemoradiotherapy and chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 289
Study: 11275924

Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 x 10(6) U over 30‐60 minutes)
Number of subjects: 397
Study: 9833860

Group type: EXPERIMENTAL
Intervention: Zidovudine, didanosine, and nevirapine combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: More sensitive assay with a lower quantification limit of 20 copies/ml
Number of subjects: 0
Study: 8008541

Group type: EXPERIMENTAL
Intervention: Specialized nursing intervention for 1 year
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control condition (no specialized nursing intervention)
Number of subjects: 332
Study: 2145232

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 2.5 micrograms/kg/minute infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 5.0 micrograms/kg/minute infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus + 10.0 micrograms/kg/minute infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 5.0 micrograms/kg/minute infusion without bolus
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no bolus)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone infusion at rates greater than 5.0 micrograms/kg/minute
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone infusion
Number of subjects: 21
Study: 6994778

Group type: EXPERIMENTAL
Intervention: Guanfacine (2 to 6 mg daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine (0.3 to 0.9 mg daily)
Number of subjects: 16
Study: 31462582

Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 28686778

Group type: EXPERIMENTAL
Intervention: 2% SA topical gel enriched with botanicals
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study: 25490610

Group type: EXPERIMENTAL
Intervention: 7-day buprenorphine tapering schedule
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 28-day buprenorphine tapering schedule
Number of subjects: 516
Study: 23719234

Group type: EXPERIMENTAL
Intervention: Colistin sulphate (50 mg 4×/day) and neomycin sulphate (250 mg 4×/day) for 10 days plus nitrofurantoin (100 mg 3×/day) for 5 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Colistin and neomycin treatment
Number of subjects: 58
Study: 21035869

Group type: EXPERIMENTAL
Intervention: Alleviated positioning (avoiding supine position for 10 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Facedown positioning (strict facedown for 22 of 24 hours for 10 days)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Alleviated positioning
Number of subjects: 69

Group type: COMPARATOR
Intervention: Facedown positioning
Number of subjects: 69
Study: 19296969

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous rectus fascial sling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent self‐catheterization
Number of subjects: 0
Study: 17719313

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg, TID for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (usual drug therapy) for 6 months
Number of subjects: 50
Study: 15586837

Group type: EXPERIMENTAL
Intervention: Organizational intervention to improve guideline implementation
Number of subjects: 5678

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5678
Study: 11480529

Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gum arabic
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9726717

Group type: EXPERIMENTAL
Intervention: Beclomethasone (mean daily dose, 640 microg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salmeterol (50 microg)
Number of subjects: 30
Study: 8306750

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for 6 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 2721103

Group type: EXPERIMENTAL
Intervention: 250 mg of disulfiram daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 mg of disulfiram daily
Number of subjects: 20
Study: 783029

Group type: EXPERIMENTAL
Intervention: Caved-S
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Antacid mixture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo followed by small quantities of antacids
Number of subjects: 45
Study: 28471731

Group type: EXPERIMENTAL
Intervention: Ashwagandha root extract (300mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25617166

Group type: EXPERIMENTAL
Intervention: Patient Navigator intervention (PNs) providing coaching and assistance for 30 days post-discharge.
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1510
Study: 23810269

Group type: EXPERIMENTAL
Intervention: Daily physical activity (DPA) assessment using DigiWalker SW-200
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Functional capacity variables (six-minute walking distance, St. George Respiratory Questionnaire activity score)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Lower functional status
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Higher functional status
Number of subjects: 155
Study: 21314839

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion using Rotaflow centrifugal pump (60 cycles/min during aortic cross‐clamping)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion using Rotaflow centrifugal pump (nonpulsatile mode during aortic cross‐clamping)
Number of subjects: 32
Study: 18823774

Group type: EXPERIMENTAL
Intervention: Single-shot spinal analgesia
Number of subjects: 122

Group type: COMPARATOR
Intervention: Paracervical block
Number of subjects: 122
Study: 16399880

Group type: EXPERIMENTAL
Intervention: Web-based standardized communication system (SCS)
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Control group (1-page copy of emergency department notes by mail)
Number of subjects: 2022
Study: 15150821

Group type: EXPERIMENTAL
Intervention: (2)H-octanoic acid saliva test (OST) with 1 MJ meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: (13)C-octanoic acid breath test (OBT) with 1 MJ meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: (2)H-octanoic acid saliva test (OST) with 2 MJ meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: (13)C-octanoic acid breath test (OBT) with 2 MJ meal
Number of subjects: 12
Study: 11422002

Group type: EXPERIMENTAL
Intervention: Itraconazole (400 mg on the first day then 200 mg day‐1 for 3 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methylprednisolone with itraconazole
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 14
Study: 9288700

Group type: EXPERIMENTAL
Intervention: Estradiol valerate/cyproterone acetate (EV/CPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjugated estrogens/medroxyprogesterone acetate (CE/MPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total testosterone and dihydroepiandrosterone sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid stimulating hormone and triiodothyronine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma renin activity and blood pressure
Number of subjects: 0
Study: 8391792

Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin, given twice daily
Number of subjects: 134

Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin (UFH), adjusted-dose
Number of subjects: 134
Study: 3521857

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 29363465

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Comparison between BA and ACT
Number of subjects: 52
Study: 27362245

Group type: EXPERIMENTAL
Intervention: Purified Vero Cell Rabies Vaccine (PVRV), n = 702, 5-dose regimen
Number of subjects: 1449

Group type: COMPARATOR
Intervention: Purified Chick Embryo Cell Vaccine (PCECV), n = 747, 5-dose regimen
Number of subjects: 1449

Group type: COMPARATOR
Intervention: Comparison of both vaccines
Number of subjects: 1449
Study: 25224610

Group type: EXPERIMENTAL
Intervention: ARV-based prevention (tenofovir gel, oral tenofovir, oral Truvada)
Number of subjects: 164
Study: 22926209

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (160 U, 320 U, or 640 U antigen per dose)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (2 doses)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (1 dose)
Number of subjects: 360
Study: 20729650

Group type: EXPERIMENTAL
Intervention: Stochastic resonance stimulation plus exercise (15 subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation plus exercise (15 subjects)
Number of subjects: 30
Study: 19151687

Group type: EXPERIMENTAL
Intervention: Functional appliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Website support for data collection
Number of subjects: 0
Study: 16000352

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (5 to 10 ppm)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo (simulated flow)
Number of subjects: 420
Study: 12520632

Group type: EXPERIMENTAL
Intervention: Tolbutamide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 16
Study: 11138572

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8891887

Group type: EXPERIMENTAL
Intervention: 300 mg aspirin once daily for 2 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice daily for 2 weeks
Number of subjects: 45
Study: 1671940

Group type: EXPERIMENTAL
Intervention: HIVAC‐1e vaccine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard NY strain vaccinia virus
Number of subjects: 35
Study: 6147412

Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg, three times daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg, three times daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg, three times daily
Number of subjects: 120
Study: 30945797

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) therapy
Number of subjects: 32
Study: 30005825

Group type: EXPERIMENTAL
Intervention: Magnetic steering intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historic control (no magnetic assistance)
Number of subjects: 100
Study: 27568646

Group type: EXPERIMENTAL
Intervention: DE+SM (8 group sessions)
Number of subjects: 107

Group type: COMPARATOR
Intervention: DE (1 group session)
Number of subjects: 107
Study: 24560350

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no ESWT)
Number of subjects: 53
Study: 22948377

Group type: EXPERIMENTAL
Intervention: Squat training with whole-body vibration (WBV; frequency = 35 to 40 Hz; amplitude = 4 mm) for 12 weeks, 3 times/week
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Squat training without WBV for 12 weeks, 3 times/week
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 21135365

Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg plus clopidogrel 75 mg daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Aspirin 162 mg plus placebo daily
Number of subjects: 113
Study: 17903081

Group type: EXPERIMENTAL
Intervention: 10% lime juice
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20% lime juice
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0% (water-only)
Number of subjects: 25
Study: 15771927

Group type: EXPERIMENTAL
Intervention: Estrogen + Progestin (E+P) for 8 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Estrogen (E) for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 27
Study: 11989514

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 23

Group type: COMPARATOR
Intervention: Acemetacine and splinting
Number of subjects: 23
Study: 9701721

Group type: EXPERIMENTAL
Intervention: Nicotine users (n=15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonusers (Control group, n=15)
Number of subjects: 15
Study: 9081959

Group type: EXPERIMENTAL
Intervention: Pralidoxime (PAM) infusion, 1 gm 8 hourly for four days (total 12 gms)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single bolus dose of Pralidoxime (PAM), 1 gm immediately after admission
Number of subjects: 72
Study: 2528826

Group type: EXPERIMENTAL
Intervention: Injection therapy with lidocaine
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Injection therapy with lidocaine combined with a steroid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray with acupressure
Number of subjects: 63

Group type: COMPARATOR
Intervention: Therapy without injected medication
Number of subjects: 63
Study: 1067749

Group type: EXPERIMENTAL
Intervention: Zinc therapy (90 mg Zn2+ daily as zinc sulphate by mouth during the latter part of pregnancy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no zinc therapy)
Number of subjects: 20
Study: 31475941

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise + squat training (WBV+ST)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Squat training (ST)
Number of subjects: 41
Study: 28383410

Group type: EXPERIMENTAL
Intervention: Significant Histological Model (SHM) scoring system using serum AST, PLT, ALB, and HBV DNA (log10 IU/mL) levels
Number of subjects: 388
Study: 25888270

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 562

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 562
Study: 23980351

Group type: EXPERIMENTAL
Intervention: Yiqi Huoxue Recipe (YHR) combined with Western drugs
Number of subjects: 61

Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study: 21556957

Group type: EXPERIMENTAL
Intervention: Navigator estimates of navigation intensity
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Total number of barriers to care
Number of subjects: 139
Study: 18253162

Group type: EXPERIMENTAL
Intervention: BM/FMS group
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: FMS group
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: BM group
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (usual curriculum)
Number of subjects: 311
Study: 16701188

Group type: EXPERIMENTAL
Intervention: Preincisional (10 mL) and postoperative (10 mL) wound infiltration of 0.5% bupivacaine (group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preincisional bupivacaine (10 mL) and postoperative infiltration of placebo (normal saline solution) (group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preincisional placebo (10 mL) and postoperative bupivacaine (10 mL) (group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Preincisional (10 mL) and postoperative infiltration of placebo (10 mL) (group 4)
Number of subjects: 120
Study: 14715338

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 11699175

Group type: EXPERIMENTAL
Intervention: Panavia 21 Opaque (PO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Scotchbond Resin Cement (SRC)
Number of subjects: 64
Study: 9377663

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) activity in the blood of patients with bladder carcinoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0